Analysts Are Bullish on Top NA Stocks: Viking Holdings Ltd (VIK), CG Oncology, Inc. (CGON)
CG Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target
Goldman Sachs: The CG Oncology (CGON.US) rating was raised from neutral to buy, and the target price was $50.00.
CG Oncology Analyst Ratings
HC Wainwright & Co. : The CG Oncology (CGON.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $75.00.
CG Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
Buy Rating for CG Oncology on Strong Trial Results and Market Potential
HC Wainwright & Co. : The CG Oncology (CGON.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $75.00.
CG Oncology Analyst Ratings
CG Oncology's Cretostimogene Shows Promising Efficacy and Safety in NMIBC Treatment, Merits Buy Rating
Buy Rating Justified by CG Oncology's Cretosmogene Efficacy and Market Positioning
CG Oncology Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on CG Oncology, Maintains $75 Price Target
Cantor Fitzgerald: The CG Oncology (CGON.US) rating was confirmed and adjusted from an increase to an increase in holdings rating, with a target price of $75.00.
Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Treatment Landscape and BCG Shortage
Buy Rating Affirmed for CG Oncology on Strong Clinical Data and Market Potential
CG Oncology Analyst Ratings
No Data